Olorofim (F901318)
Invasive fungal infections (e.g., aspergillosis, including azole-resistant; infections due to Lomentospora prolificans, Scedosporium spp., and fungi in the order Mucorales)
Phase 3Active
Key Facts
Indication
Invasive fungal infections (e.g., aspergillosis, including azole-resistant; infections due to Lomentospora prolificans, Scedosporium spp., and fungi in the order Mucorales)
Phase
Phase 3
Status
Active
Company
About F2G
F2G is a clinical-stage biotech with a 20+ year history, pioneering a novel approach to antifungal therapy. The company is developing a first-in-class agent targeting rare, life-threatening fungal infections, an area with significant unmet need and growing global health concern. With a seasoned leadership team experienced in drug development and commercialization, F2G is advancing its lead candidate through clinical trials. The company operates as a private entity, positioning itself to address a challenging and high-priority infectious disease market.
View full company profile